08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
The Federal Court of Canada recently confirmed in Bank of Montreal v. Li, 2018 FC 1298 CanLII (Bank ...
Read More >
Potential merger partners of and investors in businesses that have received loans under the Paycheck...
Read More >
The Department of Labor recently issued an opinion letter with respect to a situation that does not ...
Read More >
The New Jersey Supreme Court has granted certification and will review the Appellate Division decisi...
Read More >
Three recent Delaware Court of Chancery appraisal decisions offer a wealth of guidance not only rega...
Read More >
According to the requestor, the employer informs its employees in advance that they will be eligible...
Read More >